Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.

Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE; GH Insensitivity Syndrome Collaborative Group..

J Clin Endocrinol Metab. 2007 Mar;92(3):902-10.

PMID:
17192294
2.

Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial.

Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM; MS301 Study Group..

J Clin Endocrinol Metab. 2010 Feb;95(2):611-9. doi: 10.1210/jc.2009-0570.

PMID:
19880790
3.

Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype.

Azcona C, Preece MA, Rose SJ, Fraser N, Rappaport R, Ranke MB, Savage MO.

Clin Endocrinol (Oxf). 1999 Dec;51(6):787-92.

PMID:
10619985
4.

Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.

Camacho-Hübner C, Rose S, Preece MA, Sleevi M, Storr HL, Miraki-Moud F, Minuto F, Frystyk J, Rogol A, Allan G, Sommer A, Savage MO.

J Clin Endocrinol Metab. 2006 Apr;91(4):1246-53.

PMID:
16403822
5.

Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.

Kemp SF.

BioDrugs. 2009;23(3):155-63. doi: 10.2165/00063030-200923030-00002. Review.

PMID:
19627167
6.

Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study.

Backeljauw PF, Underwood LE; GHIS Collaborative Group. Growth hormone insensitivity syndrome..

J Clin Endocrinol Metab. 2001 Apr;86(4):1504-10.

PMID:
11297575
7.

Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.

Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG.

J Clin Endocrinol Metab. 1997 Feb;82(2):629-33.

PMID:
9024266
9.
11.

Long-term auxological and pubertal outcome of patients with hereditary insulin-like growth factor-I deficiency (Laron and growth hormone-gene deletion syndrome) treated with recombinant human insulin-like growth factor-I.

Messina MF, Arrigo T, Valenzise M, Ghizzoni L, Caruso-Nicoletti M, Zucchini S, Chiabotto P, Crisafulli G, Zirilli G, De Luca F.

J Endocrinol Invest. 2011 Apr;34(4):292-5. doi: 10.3275/7109.

PMID:
20543555
12.

A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency.

Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB Jr, Gargosky SE, Nonoshita L, Rosenfeld RG.

J Clin Endocrinol Metab. 1995 Apr;80(4):1393-8.

PMID:
7536209
13.

Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.

Woods KA, Camacho-Hübner C, Bergman RN, Barter D, Clark AJ, Savage MO.

J Clin Endocrinol Metab. 2000 Apr;85(4):1407-11.

PMID:
10770174
15.

Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.

Camacho-Hübner C, Woods KA, Miraki-Moud F, Hindmarsh PC, Clark AJ, Hansson Y, Johnston A, Baxter RC, Savage MO.

J Clin Endocrinol Metab. 1999 May;84(5):1611-6.

PMID:
10323388
16.

Insulin-like growth factor-I (rhIGF-I) therapy of short stature.

Rosenbloom AL.

J Pediatr Endocrinol Metab. 2008 Apr;21(4):301-15. Review.

PMID:
18556960
17.
18.
19.

Recombinant human insulin-like growth factor-I therapy for children with growth disorders.

Richmond EJ, Rogol AD.

Adv Ther. 2008 Dec;25(12):1276-87. doi: 10.1007/s12325-008-0124-9. Review.

PMID:
19066756
20.

Final height in a patient with Laron syndrome after long-term therapy with rhlGF-I and short-term therapy with LHRH-analogue and oxandrolone during puberty.

Zucchini S, Scarano E, Baldazzi L, Mazzanti L, Pirazzoli P, Cacciari E.

J Endocrinol Invest. 2005 Mar;28(3):274-9.

PMID:
15952414
Items per page

Supplemental Content

Support Center